| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Bristol-Myers Squibb Company (NYSE: BMY)
BMY Technical Analysis
2
| As on 31st Oct 2017 BMY Share Price closed @ 61.66 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 56.80 & Sell for SHORT-TERM with Stoploss of 61.95 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BMY Share Price
| Open | 60.94 | Change | Price | % |
| High | 61.90 | 1 Day | 0.82 | 1.35 |
| Low | 60.68 | 1 Week | 0.00 | 0.00 |
| Close | 61.66 | 1 Month | -3.63 | -5.56 |
| Volume | 8233974 | 1 Year | 5.29 | 9.38 |
| 52 Week High 66.10 | 52 Week Low 46.01 | ||||
NYSE USA Most Active Stocks
| RAI | 65.40 | -2.23% |
| EMC | 29.05 | 0.97% |
| GE | 20.16 | -1.22% |
| AKS | 4.59 | -21.54% |
| PCS | 11.84 | -0.92% |
| AMD | 10.98 | 0.83% |
| WSH | 47.18 | -2.86% |
| JNS | 14.17 | -0.56% |
| XLS | 24.66 | -0.64% |
| SWY | 35.10 | -0.11% |
NYSE USA Top Gainers Stocks
NYSE USA Top Losers Stocks
| BMY Daily Charts |
BMY Intraday Charts |
Whats New @ Bazaartrend |
BMY Free Analysis |
|
|
BMY Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 62.79 |
| RESISTANCE | 62.32 |
| SUPPORT | 61.00 |
| SUPPORT | 60.53 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
BMY Target for Month October
| 4th UP TARGET | 73.82 |
| 3rd UP TARGET | 69.92 |
| 2nd UP TARGET | 67.51 |
| 1st UP TARGET | 65.1 |
| 1st DOWN TARGET | 58.22 |
| 2nd DOWN TARGET | 55.81 |
| 3rd DOWN TARGET | 53.4 |
| 4th DOWN TARGET | 49.5 |
BMY Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
BMY Target for Year 2019
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
Bristol-Myers Squibb Company ( NYSE USA Symbol : BMY )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BMY Other Details
| Segment | EQ | |
| Market Capital | 54918418432.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers - Major | |
| Offical website | http://www.bms.com | |
BMY Address
 |
345 Park Avenue New York, NY 10154 United States Phone: 212-546-4000 Fax: 212-546-4020 |
|
BMY Latest News
BMY Business Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The companyÂ’s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
